Cancer drug developer RenovoRx's Q3 net loss widens

Reuters

2025/11/14

Cancer drug developer RenovoRx's Q3 net loss widens

Overview

RenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progress
Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024
Company expects revenue growth in 2026 to offset cash burn

Outlook

RenovoRx expects revenue growth in 2026 to offset cash burn
RenovoRx plans strategic expansion with increased physician advocacy

Result Drivers

COMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption
SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$2.91 mln
Q3 Basic EPS		-$0.08
Q3 Operating Expenses		$3.41 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for RenovoRx Inc is $3.75, about 73.3% above its November 12 closing price of $1.00

Press Release: ID:nGNX8XzfdS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583120795"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583120795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583120795?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583120795","market":"fut","top_or_hot":-1,"title":"Cancer drug developer RenovoRx's Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer RenovoRx's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>RenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progress</p></li><li><p>Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024</p></li><li><p>Company expects revenue growth in 2026 to offset cash burn</p></li></ul><p><span>Outlook</span></p><ul><li><p>RenovoRx expects revenue growth in 2026 to offset cash burn</p></li><li><p>RenovoRx plans strategic expansion with increased physician advocacy</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption</p></li><li><p>SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.91 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.08</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.41 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a> is $3.75, about 73.3% above its November 12 closing price of $1.00</p></li></ul><p>Press Release: <span>ID:nGNX8XzfdS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer drug developer RenovoRx's Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer drug developer RenovoRx's Q3 net loss widens\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-14 05:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer RenovoRx's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>RenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progress</p></li><li><p>Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024</p></li><li><p>Company expects revenue growth in 2026 to offset cash burn</p></li></ul><p><span>Outlook</span></p><ul><li><p>RenovoRx expects revenue growth in 2026 to offset cash burn</p></li><li><p>RenovoRx plans strategic expansion with increased physician advocacy</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption</p></li><li><p>SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.91 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.08</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.41 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a> is $3.75, about 73.3% above its November 12 closing price of $1.00</p></li></ul><p>Press Release: <span>ID:nGNX8XzfdS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNXT","symbol_name":"RenovoRx Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP18R:1","article_id":"2583120795","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583120795","pubTimestamp":1763069880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer drug developer RenovoRx's Q3 net loss widensOverviewRenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progressNet loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNXT":"RenovoRx Inc","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"癌症药物开发商RenovoRx第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNXT":0.9},"content_text":"Cancer drug developer RenovoRx's Q3 net loss widensOverviewRenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progressNet loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024Company expects revenue growth in 2026 to offset cash burnOutlookRenovoRx expects revenue growth in 2026 to offset cash burnRenovoRx plans strategic expansion with increased physician advocacyResult DriversCOMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoptionSALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercializationKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$2.91 mlnQ3 Basic EPS-$0.08Q3 Operating Expenses$3.41 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for RenovoRx Inc is $3.75, about 73.3% above its November 12 closing price of $1.00Press Release: ID:nGNX8XzfdSFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}